Skip to Content

Drug interactions between abacavir / dolutegravir / lamivudine and Actidose Plus Sorbitol

Results for the following 2 drugs:
abacavir/dolutegravir/lamivudine
Actidose Plus Sorbitol (charcoal/sorbitol)

Interactions between your drugs

Moderate

lamiVUDine sorbitol

Applies to: abacavir / dolutegravir / lamivudine and Actidose Plus Sorbitol (charcoal / sorbitol)

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Sorbitol may decrease the serum concentration of lamivudine. The mechanism of interaction has not been established. In an open-label, randomized sequence, 4-period, crossover study of 16 healthy adult subjects, a single 300 mg dose of lamivudine oral solution was administered alone or in combination with a single 3.2 g, 10.2 g, or 13.4 g dose of sorbitol oral solution. Coadministration of lamivudine with sorbitol resulted in dose-dependent decreases in lamivudine AUC (14%, 32%, and 36%) and Cmax (28%, 52%, and 55%).

MANAGEMENT: When possible, avoid use of lamivudine with products that contain osmotic polyalcohols (e.g., sorbitol) or monosaccharide alcohols (e.g., lactitol, mannitol). If coadministration cannot be avoided, more frequent monitoring of viral load should be considered.

References

  1. Adkison K, Wolstenholme A, Lou Y, et al. "Effect of Sorbitol on the Pharmacokinetic Profile of Lamivudine Oral Solution in Adults: An Open-label, Randomized Study." Clin Pharmacol Ther (2017):
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  4. "Product Information. Epivir (lamivudine)." Glaxo Wellcome, Research Triangle Park, NC.
View all 4 references

Drug and food interactions

Minor

dolutegravir food

Applies to: abacavir / dolutegravir / lamivudine

Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.

For clinical details see professional interaction data.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

Drug Interaction Classification

The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide